Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
about
The role of additional radiotherapy for primary central nervous system lymphomaThe role of additional radiotherapy for primary central nervous system lymphoma (PCNSL)Modified epidermal growth factor receptor (EGFR)-bearing liposomes (MRBLs) are sensitive to EGF in solutionPrimary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomeMonoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response.A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.Biology and treatment of primary central nervous system lymphoma.Treatment options for central nervous system lymphomas in immunocompetent patients.Primary brain T-cell lymphoma of the lymphoblastic type presenting as altered mental status.Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade).High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.Multimodality imaging of primary CNS lymphoma in immunocompetent patients.Radiation therapy for older patients with brain tumorsPoint/counterpoint: is there a role for radiotherapy in the treatment of primary CNS lymphoma?Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.Progress in central nervous system lymphomas.Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatmentHigh-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches.Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma.Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohortHigh-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphomaInfluence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphomaPharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patientsAdult T-cell lymphoma/leukemia presenting as isolated central nervous system T-cell lymphoma.Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoCHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphomaDifferential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomasSuccessful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma GroupLeukoencephalopathy and disseminated necrotizing leukoencephalopathy following intrathecal methotrexate chemotherapy and radiation therapy for central nerve system lymphoma or leukemia.Cognitive functions in primary CNS lymphoma after single or combined modality regimens.A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcomeHigh dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease.
P2860
Q24193995-77C9E8BD-0B2D-4EF9-B706-F0672ECC5E44Q24236186-6AF88BCD-306E-4130-A2B4-566E9649A34EQ28476290-07C0CC0C-FD63-4812-A4C2-4EEB34B05EBCQ30411362-4F142E99-C029-46EA-BE05-D1E12D1939CFQ30457046-7A18B883-B151-42D6-B600-E0E83A76F7D7Q33217186-71B9DBB3-F945-430C-97B2-4607C862F5B4Q33381778-60237DDA-FBDB-4CA2-B1E5-A8F3CF16AE3EQ33409443-4AE9BAEC-2160-4F43-8CFF-F4AAA351707DQ33416656-81A496B5-358C-45D9-9E85-351546A3A7CBQ33475480-EA1C0670-ADDA-480C-B958-BE45EEA05853Q33510785-A586917C-D108-4CD2-9046-0BD11EE2252CQ33572213-3E014DAB-0B8E-4BCE-A245-6A6A6B508C06Q33583302-2AA98D41-61C3-4C62-B3C1-905B46428A00Q33626490-C47283EA-9EEF-4527-9AC0-FCE9D69E7724Q33792304-611555B8-4FA5-4F51-A67B-30980506DBEEQ33815025-AB9D7F78-72D1-490C-AA12-E76B4F3C21D8Q33894497-1A11F8CE-FA57-4681-8F0C-20F3CB77F7E7Q33906988-61137883-6F33-46B3-9BA4-7BBDC7C11CBFQ33934406-3E9EA475-533C-4A1C-A885-2972867BEF7BQ33946604-BD53F07C-69EE-486C-878F-F919758AB4B7Q33981252-907694AC-D380-4E41-ACB9-77D89A428361Q34021952-5087452D-4230-4224-9D4A-A1F90EAB3585Q34043390-0FE4BF6F-9006-4E5A-BA83-1B9C8E118064Q34132849-49ADB520-C91B-49D1-B86D-1CDB06CB541AQ34132988-988BF0CD-6134-4DD4-9E74-0148B6C44BEEQ34174899-9E526F7A-2994-4E27-8F6C-19B62CC8A9C2Q34190457-0CA467CE-E9A7-485E-B959-342492C8A253Q34753447-3F2EAD40-5B2A-4EBB-AFE9-14127F7FA03DQ34789238-5AC4AD7D-27B2-4F09-9713-C62DEB1036DAQ34837626-8AC240A1-9145-4C63-A4BF-59781648B7C5Q34943963-24977F67-2419-479D-937E-929A5D09B279Q35105505-CE050C43-3AD1-43E8-880D-590909A3A753Q35225279-407186B6-DC76-4B60-BBF4-8A7635AFB68FQ35236072-4EE8A133-4D85-4B5A-9F77-7415B6080F79Q35627088-4C3EF4F5-FE33-4B14-9CFA-DA1376F5E9B9Q35633840-EF5D1971-0B76-4AE6-8518-BA33580DFF4DQ35639567-ADFB5A8B-0330-421A-91EA-DBAD6B530A35Q35718598-98AF18F6-AFF4-4799-A9B3-FBDF3C327127Q35799389-DD18ED40-35C9-466C-964D-600D2CC5F6C5Q35825003-ACE57CD0-49B8-42AA-B047-3FBA0C131C19
P2860
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Combination chemotherapy and r ...... py Oncology Group Study 93-10.
@ast
Combination chemotherapy and r ...... py Oncology Group Study 93-10.
@en
Combination chemotherapy and r ...... py Oncology Group Study 93-10.
@nl
type
label
Combination chemotherapy and r ...... py Oncology Group Study 93-10.
@ast
Combination chemotherapy and r ...... py Oncology Group Study 93-10.
@en
Combination chemotherapy and r ...... py Oncology Group Study 93-10.
@nl
prefLabel
Combination chemotherapy and r ...... py Oncology Group Study 93-10.
@ast
Combination chemotherapy and r ...... py Oncology Group Study 93-10.
@en
Combination chemotherapy and r ...... py Oncology Group Study 93-10.
@nl
P2093
P356
P1476
Combination chemotherapy and r ...... py Oncology Group Study 93-10.
@en
P2093
Barbara Fisher
Christopher J Schultz
Radiation Therapy Oncology Group Study 93-10
S Clifford Schold
Wendy Seiferheld
P304
P356
10.1200/JCO.2002.11.013
P407
P577
2002-12-01T00:00:00Z